IBDEI0SY ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13576,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,13576,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,13576,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,13577,0)
 ;;=Z85.528^^53^594^89
 ;;^UTILITY(U,$J,358.3,13577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13577,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,13577,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,13577,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,13578,0)
 ;;=Z85.6^^53^594^80
 ;;^UTILITY(U,$J,358.3,13578,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13578,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,13578,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,13578,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,13579,0)
 ;;=Z85.72^^53^594^104
 ;;^UTILITY(U,$J,358.3,13579,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13579,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,13579,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,13579,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,13580,0)
 ;;=Z85.79^^53^594^94
 ;;^UTILITY(U,$J,358.3,13580,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13580,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,13580,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,13580,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,13581,0)
 ;;=Z85.820^^53^594^83
 ;;^UTILITY(U,$J,358.3,13581,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13581,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,13581,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,13581,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,13582,0)
 ;;=Z85.828^^53^594^98
 ;;^UTILITY(U,$J,358.3,13582,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13582,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,13582,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,13582,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,13583,0)
 ;;=Z85.71^^53^594^78
 ;;^UTILITY(U,$J,358.3,13583,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13583,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,13583,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,13583,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,13584,0)
 ;;=Z65.8^^53^594^138
 ;;^UTILITY(U,$J,358.3,13584,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13584,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,13584,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,13584,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,13585,0)
 ;;=Z86.11^^53^594^115
 ;;^UTILITY(U,$J,358.3,13585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13585,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,13585,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,13585,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,13586,0)
 ;;=Z86.13^^53^594^82
 ;;^UTILITY(U,$J,358.3,13586,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13586,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,13586,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,13586,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,13587,0)
 ;;=Z86.73^^53^594^112
 ;;^UTILITY(U,$J,358.3,13587,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13587,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,13587,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,13587,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,13588,0)
 ;;=Z86.79^^53^594^75
 ;;^UTILITY(U,$J,358.3,13588,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13588,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,13588,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,13588,2)
 ;;=^5063479
